A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health
Latest Information Update: 24 Mar 2025
At a glance
- Drugs VAC 52416 (Primary) ; JNJ 63871860; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Bacterial infections; Escherichia coli infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Janssen Research & Development
Most Recent Events
- 19 Mar 2025 Status changed from active, no longer recruiting to completed.
- 25 Oct 2022 Planned End Date changed from 10 Nov 2023 to 30 Dec 2024.
- 21 Dec 2021 Planned End Date changed from 23 Nov 2023 to 10 Nov 2023.